The key dates for KRAS watch­ers through the end of the year — the trail is nar­row and risks are ex­treme

6 years ago
R&D

Bain's Or­ly Mis­han joins Pfiz­er's neu­ro spin­out Cerev­el; On­colyt­ic virus biotech taps Sil­la­Jen ex­ec He­le­na Chaye as ...

6 years ago
Peer Review

A bud­get biotech you like­ly nev­er heard about is set­ting a course for Wall Street with some mod­est am­bi­tions

6 years ago
Financing

Watch out Bay­er, Roche is com­ing for you with a dis­count price ri­val to the tu­mor ag­nos­tic drug you got from Loxo

6 years ago
R&D

Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

6 years ago
People
Pharma

Soar­ing De­ci­phera cap­i­tal­izes on pos­i­tive tri­al with $400M of­fer­ing; Spring­Work hires ex-For­est Labs CFO

6 years ago
News Briefing

Re­gen­eron puts fin­ish­ing touch­es on $800M ex­pan­sion project close to home

6 years ago
R&D

A PARP suc­ces­sor? Michi­gan aca­d­e­m­ic team touts po­ten­tial of an ag­ing — but still ex­per­i­men­tal — As­traZeneca drug ...

6 years ago
R&D

Ail­ing Mallinck­rodt's drug for rare, life-threat­en­ing re­nal con­di­tion clears piv­otal study

6 years ago
R&D
Pharma

New re­search ques­tions FDA’s re­liance on and in­abil­i­ty to en­force post­mar­ket­ing re­quire­ments

6 years ago
FDA+

One of the 'mir­a­cle cures' to hit the streets is re­al­ly just in­dus­tri­al bleach — and it can kill you

6 years ago
FDA+

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

6 years ago
China
Biotech Voices

On the cusp of PhI, An­gel­man-fo­cused biotech scores po­ten­tial buy­out deal from Ul­tragenyx

6 years ago
Deals

FDA en­dors­es new reg­i­men for dead­ly drug-re­sis­tant tu­ber­cu­lo­sis ram­pant in de­vel­op­ing world

6 years ago
R&D
Pharma

The re­al-world ev­i­dence project at the FDA adds Syapse to its list of part­ners in a push past tri­al bound­aries

6 years ago
R&D
FDA+

Macro­Gen­ics vs Mer­ck: An un­der­dog plans a pre­mier bout with the heavy­weight cham­pi­on of the PD-1 class

6 years ago
R&D

AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

6 years ago
People

Sen­a­tors ac­cuse Te­va, My­lan of stonewalling price fix­ing probe; Myr­i­ad Ge­net­ics shares skid on dis­mal quar­ter­ly ...

6 years ago
News Briefing

Armed with stel­lar — if niche — PhI­II da­ta, Re­gen­eron steers 'break­through' cho­les­terol drug to post-PC­SK9 wa­ters

6 years ago
R&D

Johns Hop­kins sci­en­tists raise $137M megaround for a trio of spin­outs look­ing to tack­le Alzheimer’s, Parkin­son’s ...

6 years ago
Financing
Startups

As in­vestors fret about Xyrem dura­bil­i­ty, Jazz spends $52M+ up­front to swal­low neu­ro-fo­cused biotech

6 years ago
Deals

As dis­as­ter struck, Ab­b­Vie’s Rick Gon­za­lez swooped in on Al­ler­gan with an of­fer Brent Saun­ders couldn’t say no to

6 years ago
Deals

Eli Lil­ly's Taltz beats J&J's Trem­fya in pso­ri­a­sis head-to-head — but the mar­ket­ing brawl is just be­gin­ning

6 years ago
R&D
Pharma

Biotech tar­get­ing rare heart mu­ta­tion with gene ther­a­py scores $11M in Se­ries A haul

6 years ago
Financing
Startups
First page Previous page 922923924925926927928 Next page Last page
A service from the Financial Times